Aubagio Approval Reflects FDA’s Evolving View On Multiple Sclerosis Drugs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sanofi’s teriflunomide is indicated broadly for treating relapsing forms of MS. The claim marks a departure from previously approved MS drugs, in which the specific effects seen in clinical trials are described in the Indications section. FDA said the Aubagio claim more closely reflects how physicians actually use the drugs and represents a more flexible regulatory approach that enabled approval of a second, lower dose.
You may also be interested in...
US FDA Eliminating 'Sub-Indications' From Inflammatory Bowel Disease Labels
Claims such as induction of clinical remission will now be placed in the clinical studies section for new IBD approvals.
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.